亚辉龙2025年H1研发投入1.43亿元化学发光业务竞争力再增强

Core Viewpoint - The company, YHLO Biotech (688575.SH), reported its 2025 semi-annual performance, showcasing significant revenue and profit growth, alongside substantial investments in research and development, enhancing its competitive position in the in vitro diagnostics market [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 808 million yuan and a net profit attributable to shareholders of 26.27 million yuan, with a non-recurring net profit of 50.03 million yuan [1] - The total assets of the company stood at 4.299 billion yuan, while net assets were 2.668 billion yuan [1] Research and Development - The company invested 143 million yuan in research and development during the first half of 2025 [1] - It received 14 new domestic registration certificates for chemical luminescence testing reagents, including products for thrombosis, hepatitis B quantification, bone metabolism, and various other health conditions [1] - As of the end of the reporting period, the company had obtained 184 registration certificates for chemical luminescence diagnostic projects both domestically and internationally, with 62 projects focused on autoimmune diagnostics, indicating an increasing market competitiveness [1] Industry Position - YHLO Biotech is a research-driven medical device company that has developed a range of in vitro diagnostic instruments and accompanying reagents based on various technological platforms, including chemical luminescence and enzyme-linked immunosorbent assays [1] - The company has over a decade of innovation and research experience, establishing a strong capability in both research and industrialization within the in vitro diagnostics field [1]